Hjem › Mesoteliom › Ohio
Mesoteliom kliniske forsøg i Ohio
9 studier for Mesoteliom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
SW-682 in Advanced Solid Tumors
- University Hospital of Cleveland, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06251310Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04981119Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT06566079Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Ohio State University, Columbus
RekruttererFase 1/2
Alder 18 til 90 · Alle køn · Opdateret 6. jul. 2026 · NCT06710756Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 til 110 · Alle køn · Opdateret 29. jun. 2026 · NCT02012699A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 12. jun. 2026 · NCT06051695Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alle aldre · Alle køn · Opdateret 9. mar. 2026 · NCT04792463VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Taylor Cancer Research Center (site 204), Maumee
RekruttererFase 1/2
Alder 18 til 80 · Alle køn · Opdateret 11. dec. 2025 · NCT03556228Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.